Advertisement

Clinical Rheumatology

, Volume 25, Issue 6, pp 794–800 | Cite as

Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey

  • Jane Zochling
  • Martin H. J. Bohl-Bühler
  • Xenofon Baraliakos
  • Ernst Feldtkeller
  • Jürgen BraunEmail author
Original Article

Abstract

The objective of the study is to describe the use, clinical efficacy, and toxicity of nonsteroidal anti-inflammatory drug (NSAID) therapy in patients with ankylosing spondylitis (AS). A cross-sectional population study of 1,080 AS patients was carried out by a written questionnaire in the year 2000. Seventy-eight percent of AS patients had regularly taken NSAIDs for their disease 12 months prior to the study. Most AS patients commonly used diclofenac, naproxen and indomethacin. AS patients were generally rather satisfied with the efficacy of their therapy where 19.1% reported complete pain control, 26.8% reported pain reduction to one quarter, and a further 34.4% reported pain reduction to one half. However, over 20% of patients taking NSAIDs still reported insufficient pain control and more than 40% changed the NSAID due to lack of efficacy. One quarter of AS patients reported severe side effects from their treatment, most commonly abdominal pain, headache and dizziness, and nausea. There was no effect on age or duration of disease on the occurrence of NSAID-related side effects. Medications were commonly ceased or changed due to inefficacy or side effects. The percentage of AS patients reporting changing their NSAID due to side effects ranged from 10.5% for celecoxib to 31.4% for indomethacin. We conclude that NSAIDs are effective in the management of inflammatory symptoms of many, but not all, patients with AS. There is a significant side effect profile, which frequently results in medication change or cessation. Anti-tumor necrosis factor therapy may reduce the need for intensive long-term NSAID therapy in AS.

Keywords

Ankylosing spondylitis Nonsteroidal anti-inflammatory drugs Population study 

References

  1. 1.
    van der Linden S, van Tubergen A, Hidding A (2002) Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 20[6 Suppl 28]:S60–S64PubMedGoogle Scholar
  2. 2.
    Miceli-Richard C, Dougados M (2002) NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S65–S66PubMedGoogle Scholar
  3. 3.
    Dougados M (2001) Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 68(6):557–563CrossRefPubMedGoogle Scholar
  4. 4.
    Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides—the current state. Rheumatology 43(9):1072–1084CrossRefPubMedGoogle Scholar
  5. 5.
    Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57(2):85–89PubMedGoogle Scholar
  6. 6.
    Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, Benhamou C, Blotman F, Pattin S, Paolaggi JB (1991) Evaluation des critères de spondylarthropathies d’Amor et de l’European spondylarthropathy study group (ESSG). Une étude transversale de 2,228 patients. Ann Med Interne (Paris) 142(2):85–89Google Scholar
  7. 7.
    Coles LS, Fries JF, Kraines RG, Roth SH (1983) From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 74(5):820–828CrossRefPubMedGoogle Scholar
  8. 8.
    Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340(24):1888–1899CrossRefPubMedGoogle Scholar
  9. 9.
    Laine L (2003) Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 25[2 Suppl]:S32–S40CrossRefPubMedGoogle Scholar
  10. 10.
    Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66PubMedGoogle Scholar
  11. 11.
    Zochling J, Bohl-Bühler MHJ, Baraliakos X, Feldtkeller E, Braun J (2005) The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clin Rheumatol Online First, DOI  10.1007/s10067-005-0130-0
  12. 12.
    Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Ziedler H, Herman H (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44(1):180–185CrossRefPubMedGoogle Scholar
  13. 13.
    Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131PubMedGoogle Scholar
  14. 14.
    Dougados M, Revel M, Khan M (1998) Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 12(4):717–736PubMedGoogle Scholar
  15. 15.
    Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German collaborative arthritis centers. J Rheumatol 27(3):613–622PubMedGoogle Scholar
  16. 16.
    Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S16–S22PubMedGoogle Scholar
  17. 17.
    Hardo PG, Chalmers DM, Jakeways M, Wright V, Axon AT (1993) Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract 47(5):241–242PubMedGoogle Scholar
  18. 18.
    Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105(1B):31S–38SCrossRefPubMedGoogle Scholar
  19. 19.
    Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004) Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63(7):759–766CrossRefPubMedGoogle Scholar
  20. 20.
    Feldtkeller E, Bruckel J, Khan MA (2000) Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 12:239–247CrossRefPubMedGoogle Scholar
  21. 21.
    Feldtkeller E (1999) Erkrankungsalter und Diagnoseverzögerung bei Spondylarthropathien. Z Rheumatol 58:21–30CrossRefPubMedGoogle Scholar
  22. 22.
    Feldtkeller E, Lemmel EM (1999) Zur Situation von Spondyloarthritis-Patienten. Ergebnisse einer Repräsentativbefragung der Deutschen Vereinigung Morbus Bechterew. Novartis Pharma, NurembergGoogle Scholar
  23. 23.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedGoogle Scholar
  24. 24.
    Gran JT (1985) An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 4(2):161–169CrossRefPubMedGoogle Scholar
  25. 25.
    Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA (2004) Epidemiology of ankylosing spondylitis in Northwest Greece, 1983–2002. Rheumatology 43(5):615–618CrossRefPubMedGoogle Scholar
  26. 26.
    Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, Northern Norway. Ann Rheum Dis 44(6):359–367PubMedCrossRefGoogle Scholar
  27. 27.
    Gomor B, Gyodi E, Bakos L (1977) Distribution of HLA B27 and ankylosing spondylitis in the Hungarian population. J Rheumatol 3:33–35 (Suppl)Google Scholar
  28. 28.
    Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW (2001) Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol 69(6):1026–1036CrossRefPubMedGoogle Scholar
  29. 29.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675CrossRefPubMedGoogle Scholar
  30. 30.
    Brandt J, Sieper J, Braun J (2002) Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S106–S110PubMedGoogle Scholar
  31. 31.
    Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Jane Zochling
    • 1
  • Martin H. J. Bohl-Bühler
    • 2
  • Xenofon Baraliakos
    • 1
  • Ernst Feldtkeller
    • 3
  • Jürgen Braun
    • 1
    Email author
  1. 1.Rheumazentrum Ruhrgebiet, St. Josefs-KrankenhausHerneGermany
  2. 2.KB-Practice for Internal MedicineBrandenburgGermany
  3. 3.Ankylosing Spondylitis International FederationMunichGermany

Personalised recommendations